基于网络药理学和实验验证研究柴胡疏肝散治疗慢性萎缩性胃炎的作用机制＊

目的 通过网络药理学的方法进行预测，再深一步进行动物实验验证来研究柴胡疏肝散治疗CAG的作用机制。方法 首先在TCMSP数据库中检索柴胡疏肝散的所有活性成分与药物靶点；通过收集PharmGkb、OMIM、GeneCards和DrugBank数据库中收录的慢性萎缩性胃炎的相关靶点。将药物靶点与疾病靶点进行映射筛选出交集靶点，将得到的交集靶点构建PPI网络与活性成分-共同靶点网络，并对其进行GO和KEGG富集分析。最后利用Vina软件进行分子对接实验验证，并通过免疫印迹法验证柴胡疏肝散对两种受体蛋白EGFR和STAT1的影响。结果 最终筛选得到柴胡疏肝散活性成分104个，潜在靶点238个，与慢性萎缩性胃炎的交集靶点52个；GO与KEGG富集分析分别得到2166条目和148条目，主要涉及到JAK-STAT信号通路、TNF信号通路、HIF-1信号通路等；分子对接结果显示EGFR、STAT1两个靶点能够与核心活性成分能够自发结合成较为稳定的构像；免疫印迹法实验证明柴胡疏肝散能够降低大鼠胃黏膜组织EGFR和STAT1蛋白表达。结论 通过网络药理学和实验验证，发现柴胡疏肝散可能通过调节EGFR和STAT1蛋白表达来共同调控胃黏膜细胞增殖与凋亡，进而发挥着治疗慢性萎缩性胃炎的效果，为深入进行柴胡疏肝散治疗慢性萎缩性胃炎的作用机制研究提供新思路和新方法。     

Inverse correlation between gastroesophageal reflux disease and atrophic gastritis assessed by endoscopy and serology

BACKGROUND Helicobacter pylori(H.pylori)infection is known to prevent the occurrence of gastroesophageal reflux disease(GERD)by inducing gastric mucosal atrophy.However,little is known about the relationship between atrophic gastritis(AG)and GERD.AIM To confirm the inverse correlation between AG and the occurrence and severity of GERD.METHODS Individuals receiving health checkups who underwent upper gastrointestinal endoscopy at Seoul National University Healthcare System Gangnam Center were included.The grade of reflux esophagitis was evaluated according to the Los Angeles classification.Endoscopic AG(EAG)was categorized into six grades.Serologic AG(SAG)was defined as pepsinogen I≤70 ng/m L and pepsinogen I/II ratio≤3.0.The association between the extent of EAG and SAG and the occurrence and severity of GERD was evaluated using multivariate logistic regression analysis.RESULTS In total,4684 individuals with GERD were compared with 21901 healthy controls.In multivariate logistic regression analysis,advanced age,male sex,body mass index>23 kg/m2,presence of metabolic syndrome,current smoking,and alcohol consumption were associated with an increased risk of GERD.Seropositivity for H.pylori immunoglobulin G antibodies was associated with a decreased risk of GERD.There was an inverse correlation between the extent of EAG and occurrence of GERD:Odds ratio(OR),1.01[95%confidence interval(CI):0.90-1.14]in C1,0.87(0.78-0.97)in C2,0.71(0.62-0.80)in C3,0.52(0.44-0.61)in O1,0.37(0.29-0.48)in O2,and 0.28(0.18-0.43)in O3.Additionally,the extent of EAG showed an inverse correlation with the severity of GERD.The presence of SAG was correlated with a reduced risk of GERD(OR=0.49,95%CI:0.28-0.87,P=0.014).CONCLUSION The extent of EAG and SAG exhibited strong inverse relationships with the occurrence and severity of GERD.AG followed by H.pylori infection may be independently protect against GERD.     

人参、白术有效组分群对慢性萎缩性胃炎大鼠口腔、肠道菌群的影响

目的研究人参、白术有效组分群对慢性萎缩性胃炎大鼠口腔、肠道菌群的影响。方法将大鼠随机分为空白组、模型组、给药(人参白术有效组分群)组,用主动免疫法复制慢性萎缩性胃炎模型。HE染色、扫描电子显微技术观察胃黏膜组织显微及超微结构,高通量测序技术检测肠道及口腔菌群,利用SPSS软件进行相关性分析。结果人参、白术有效组分群能改善慢性萎缩性胃炎大鼠胃组织病理形态(P<0.05);增加大鼠肠道、口腔菌群多样性及丰富度(P<0.05);减少肠道、口腔中致病菌群(普雷沃氏菌科_UCG-003、梭杆菌属)的数目(P<0.05)。其中,大鼠病理学评分与其口腔、肠道菌群的丰度、多样性以及门、属水平上的差异菌具有相关性(P<0.05)。结论人参、白术有效组分群对慢性萎缩性胃炎大鼠有良好的保护作用,缓解胃黏膜萎缩,其作用机制可能与改善肠道和口腔菌群有关。     

肠胃清胶囊治疗慢性胃炎60例

目的：观察自制中药肠胃清胶囊治疗慢性胃炎的临床效果。方法：根据《中药新药临床研究指导原则》的标准，采用自身前后对比的方法，对临床症状、体征及相关检查从中医两个方面进行治疗前后对比。结果：肠胃清胶囊对慢性胃炎的症状、体征有明显疗效，对胃黏膜镜下病变及组织学变化亦有明显的改善作用。结论：肠胃清胶囊对偏热偏实型慢性胃炎具有明显疗效。临床观察中未发现毒性和不良反应。     

中西医结合治疗幽门螺杆菌相关性胃炎临床观察

目的：观察中西医结合治疗幽门螺杆菌（Hp）相关性胃炎的临床疗效。方法：对照组24例，采用西医三联疗法（奥美拉唑、克拉霉素、阿莫西林）治疗，治疗组28例在西医三联疗法的基础上加用中药治疗，两组均用药7天，后口服奥关拉唑片至1个月。结果：两组总有效率及Hp根除率比较差异均有显著意义（P〈0．05），治疗组疗效优于对照组。结论：中西医结合治疗幽门螺杆菌相关性胃炎疗效好。     

胃幽门弯曲菌感染对胃癌发生影响的探讨

应用Warthin-starry镀银技术检查胃幽门弯曲菌,对中国胃癌高发区及美国胃癌高发区新奥尔良检查了300例具有胃症状的胃粘膜标本。结果发现幽门弯曲菌阳性率为60～62%,并且看到这种细菌的感染与慢性胃炎病变的程度有明显的关系。本文探讨了幽门弯曲菌的感染与胃癌癌前病变的关系。     

新疆维吾尔族慢性胃炎患者HLA-DRB1等位基因与幽门螺杆菌感染的关系

目的研究新疆维吾尔族慢性胃炎患者HLA-DRB1等位基因与幽门螺杆菌（Hp）感染的关系。方法采用幽门螺杆菌分离培养技术检测33例维吾尔族慢性胃炎患者幽门螺杆菌感染情况,采用PCR-SSP检测HLA-DRB1＊0405、HLA-DRB1＊08、HLA-DRB1＊12等位基因,并与36例汉族慢性胃炎患者进行比较。结果1）新疆维吾尔族慢性胃炎患者Hp阳性率（78.8%）显著高于汉族慢性胃炎患者（58.3%）（P〈0.05）;2）维吾尔族、汉族慢性胃炎患者Hp感染与HLA-DRB1＊0405、HLA-DRB1＊08、HLA-DRB1＊12等位基因无相关性（P〉0.05）。结论1）维吾尔族慢性胃炎患者Hp感染率高于汉族慢性胃炎患者;2）维吾尔族、汉族慢性胃炎患者Hp感染与HLA-DRB1＊0405、HLA-DRB1＊08、HLA-DRB1＊12等位基因无关。     

Duodenogastric reflux after choledochoduodenostomy

Duodenogastric reflux (DGR) has been implicated in several disease processes. The present study was carried out to document the incidence and evaluate the clinical significance of DGR after choledochoduodenostomy (CDD). A total of 13 patients who had undergone cholecystectomy with a standard side-to-side CDD for choledocholithiasis or chronic pancreatitis were studied by symptom evaluation, scintigraphy, endoscopy, and gastric mucosal histology at least 6 months after surgery. The scintigraphic findings were then compared with those of 10 patients who had undergone cholecystectomy alone. Only two patients (15%) had mild dyspeptic symptoms. The incidence of DGR after CDD was 69% compared to 20% in the cholecystectomy alone group (P < 0.05). In the majority of patients the DGR was only mild to moderate and the severity correlated well with the degree of endoscopic gastritis, but not with the clinical symptoms or histological findings. These results indicate that while CDD is associated with a high incidence of DGR, its occurrence does not produce significant clinical symptoms.     

糜烂性胃炎462例分析

目的探讨糜烂性胃炎(EG)在内镜下的形态、分布及预后.方法对1997年1月～2003年12月经内镜确诊的462例糜烂性胃炎进行分析.结果462例中,男性336例,女性126例,男女之比2.67:1.隆起糜烂型185例,占40.04%;平坦糜烂型277例,占59.96%.胃窦部363例,占总数的78.57%;其中隆起糜烂型173例,占47.66%;平坦糜烂型190例,占52.34%,两型之间差异无显著性(P＞0.05).胃高位99例,占总数的21.43%;其中隆起糜烂型12例,占12.12%;平坦糜烂型87例,占87.88%;胃窦部隆起糜烂型占47.66%(173/363),胃高位隆起糜烂型占12.12%(12/99);隆起糜烂型和平坦糜烂型HP感染率分别为83.78%和27.08%,差异有非常显著性(χ2=142.68,P＜0.01).结论胃窦部与胃高位糜烂性胃炎的发病率均以男性为主,其中隆起糜烂型好发于胃窦部,而胃高位以平坦糜烂型为主.     

莫沙必利联合铝碳酸镁治疗胆汁反流性胃炎疗效观察

目的　探讨铝碳酸镁及莫沙必利对胆汁反流性胃炎的疗效。方法　将 45例经胃镜证实胃液内有胆汁贮留及胃窦明显炎症的胆汁反流性胃炎随机分为A、B、C组。A组 ( 15例 )服用莫沙必利 5mg/次 ,3次 /d ;B组 ( 16例 )服用铝碳酸镁 1.0g/次 ,3次/d ;C组 ( 14例 )同时服用西沙必利和铝碳酸镁 ,剂量同A、B组。治疗 4周后观察上腹痛、腹胀、恶心、呕吐症状变化。结果　治疗后三组患者症状均明显减轻 ( P <0 .0 5或 <0 .0 1) ,C组症状改善更明显 ( P <0 .0 5或 <0 .0 1)。结论　莫沙必利、铝碳酸镁联合应用治疗肝胆汁反流性胃炎的疗效优于单一用药